Partnership to advance regulatory submissions using real-world evidence
Sanofi (NJ, USA) and Aetion (NY, USA) have announced their partnership that will integrate their respective real-world data platforms, with the aim of advancing more efficient, transparent use of real-world evidence (RWE) in regulatory submissions.
Sanofi (NJ, USA) and Aetion (NY, USA) have jointly announced their partnership that will integrate DARWIN – Sanofi’s real-world data platform – with the Aetion Evidence Platform®; the collaboration aims to advance the more efficient, transparent use of real-world evidence (RWE) in regulatory decision making.
Both Sanofi and Aetion have invested heavily in their RWE platforms, recognizing the potential role real-world evidence could play in the generation of more accurate, rapid and cost-effective research.
Sanofi hopes that by integrating DARWIN – which compiles and analyzes de-identified data on millions of patients with various diseases – with the Aetion Evidence Platform®, which employs real-world data to provide important, validated answers concerning the effectiveness, safety and value of drugs, a new pathway for the development and application of medical treatments, supported by regulatory grade analytics, may be revealed.
Bernard Hamelin, Global Head of Medical Evidence Generation at Sanofi, stated: “By integrating these platforms, we strive to make faster, more informed decisions with the potential to lead to first-in-class and best-in-class treatments that could change the practice of medicine.”
Carolyn Magill, CEO of Aetion, commented: “Our work with Sanofi further validates the value and potential for real-world evidence in drug development. Our companies share a common goal of using the best available data to get the right treatment to the right patient as quickly and efficiently as possible.”
You may also be interested in: